Pooled Analysis From Sanofi's BOREAS And NOTUS Phase 3 Studies Showed That Dupixent Reduced Exacerbations And Improved Lung Function Vs. Placebo For Uncontrolled Chronic Obstructive Pulmonary Disease And Evidence Of Type 2 Inflammation
Portfolio Pulse from Benzinga Newsdesk
Sanofi and Regeneron presented results from their Phase 3 studies, BOREAS and NOTUS, showing that Dupixent significantly reduced exacerbations and improved lung function in patients with uncontrolled COPD and Type 2 inflammation. These findings were shared at the 2024 ERS International Congress.
September 10, 2024 | 10:55 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron, in collaboration with Sanofi, reports positive Phase 3 results for Dupixent in COPD, which may enhance its product portfolio and revenue.
The successful Phase 3 results for Dupixent, developed with Sanofi, could strengthen Regeneron's product offerings and lead to increased revenue.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Sanofi's Dupixent shows positive results in Phase 3 studies for COPD, potentially boosting its market position and revenue.
The positive results from the Phase 3 studies could enhance Sanofi's market position in the COPD treatment space, potentially leading to increased revenue from Dupixent.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80